Skyhawk shared data at the 15 month mark for SKY-0515 treatment in people with HD in their Phase 1/2 trial. The drug is working as designed and there are some encouraging signs that it could be helpful for some symptoms of HD. 

⏱️8 min read | What if nutrition is one of the warning lights we should be checking earlier in Huntington’s disease? New research suggests simple nutrition measures may help identify when people with HD need extra support.

⏱️7 min read | A review of 23 studies found that EEG changes were linked to disease progression and clinical measures in HD. While more research is needed, EEG holds potential to become a simple, non-invasive biomarker for monitoring HD over time.